About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Anti-Tau Drug Decreases Tau Tangles in Alzheimer's Disease Models, Study Shows

by Kathy Jones on July 23, 2012 at 9:24 PM
Font : A-A+

 Anti-Tau Drug Decreases Tau Tangles in Alzheimer's Disease Models, Study Shows

Results of clinical trials involving drugs intended to decrease amyloid production are being released on a timely basis in recent years. At the same time, clinical trials of drugs targeting other disease proteins, such as tau, are in their initial phases.

Advertisement

Penn Medicine research presented today at the 2012 Alzheimer's Association International Conference (AAIC) shows that an anti-tau treatment called epithilone D (EpoD) was effective in preventing and intervening the progress of Alzheimer's disease in animal models, improving neuron function and cognition, as well as decreasing tau pathology. By targeting tau, the drug aims to stabilize microtubules, which help support and transport of essential nutrients and information between cells. When tau malfunctions, microtubules break and tau accumulates into tangles. "This drug effectively hits a tau target by correcting tau loss of function, thereby stabilizing microtubules and offsetting the loss of tau due to its formation into neurofibrillary tangles in animal models, which suggests that this could be an important option to mediate tau function in Alzheimer's and other tau-based neurodegenerative diseases," said John Trojanowski, MD, PhD, professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania. "In addition to drugs targeting amyloid, which may not work in advanced Alzheimer's disease, our hope is that this and other anti-tau drugs can be tested in people with Alzheimer's disease to determine whether stabilizing microtubules damaged by malfunctioning tau protein may improve clinical and pathological outcomes." The drug, identified through Penn's Center for Neurodegenerative Disease Research (CNDR) Drug Discovery Program, was previously shown to prevent further neurological damage and improve cognitive performance in animal models*. The Penn research team includes senior investigator Bin Zhang, MD, and Kurt Brunden, PhD, director of Drug Discovery at CNDR.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Can Weight Loss be Achieved by Drinking Water?
Can Exercise Counts Boost Your Life Counts? 
Prevent Hacking of Medical Devices: FDA Sounds Alarm
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Alzheimers Disease Drug Toxicity Signature Drug Toxicity Creutzfeldt-Jakob Disease Diet and Alzheimer´s Disease Genetics of Alzheimer´s disease Mini-Mental Scale (Cognitive Function Test) 

Most Popular on Medindia

Loram (2 mg) (Lorazepam) Hearing Loss Calculator Noscaphene (Noscapine) Pregnancy Confirmation Calculator Iron Intake Calculator Accident and Trauma Care Blood Donation - Recipients Post-Nasal Drip Diaphragmatic Hernia Calculate Ideal Weight for Infants

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use